Skip to main content
Clinical Trials/NCT00680706
NCT00680706
Completed
Phase 2

Targeting Myocardial Energy Metabolism for the Treatment of Acute Heart Failure: The Effect of Thiamine on Biochemical, Electrocardiographic and Respiratory Parameters in Hospitalized Patients.

Baystate Medical Center2 sites in 1 country131 target enrollmentJanuary 2008

Overview

Phase
Phase 2
Intervention
Placebo
Conditions
Heart Failure
Sponsor
Baystate Medical Center
Enrollment
131
Locations
2
Primary Endpoint
Effect of Thiamine Supplementation on Dyspnea
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Heart failure remains an increasing cause of morbidity and mortality in the United States even in the face of recent advances in the treatment of cardiovascular disease. There is an urgent need to reevaluate the treatment of heart failure. Shifting substrate utilization used in energy metabolism from fatty acids to glucose is beneficial to the heart presumably by increasing the efficiency of ATP production. Several new drugs for the treatment of cardiac ischemia work by this mechanism. There is increasing evidence that patients with heart failure may also benefit by the same type of intervention. Patients with heart failure are known to have low serum thiamine levels because of poor dietary intake and increased urinary excretion. Inadequate thiamine will deleteriously shift substrate utilization from glucose to fatty acids.

We hypothesize that thiamine supplementation will be beneficial for patients with heart failure by increasing glucose and decreasing fatty acid utilization. This will be initially tested in a pilot double-blinded placebo controlled study of thiamine supplementation in diabetic and non-diabetic patients presenting to the emergency department with acute decompensated heart failure.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
June 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Howard Smithline

Chief, Emergency Medicine Research

Baystate Medical Center

Eligibility Criteria

Inclusion Criteria

  • History of heart failure on a loop diuretic.
  • Worsening dyspnea over the past 24 hours.
  • Currently dyspneic sitting or supine, on or off oxygen.
  • Radiographic cephalization of vessels. This criteria is not needed if the patient has no other reason for being dyspneic after being evaluated in the emergency department.
  • Elevated NT pro-BNP (\>450).
  • Able to communicate in English or Spanish.
  • Able and willing to provide informed consent.
  • Age \> 18 years.
  • A primary admitting diagnosis of acute decompensated heart failure.

Exclusion Criteria

  • Renal failure on dialysis.
  • Severe valvular disease.
  • EKG criteria for acute myocardial infarction (ST segment elevation \> 1mm on two contiguous leads).
  • Initial troponin elevated.
  • Ventricular arrhythmia (ventricular tachycardia or fibrillation).
  • Supraventricular arrhythmia (atrial fibrillation / flutter) with a ventricular rate \>120 beats per minute.
  • Taking a daily thiamine supplementation (any multivitamin or specific thiamine supplementation within the past 2 weeks. Fortified foods, such as cereals, are acceptable
  • Taking a daily fatty acid supplement.
  • Pregnancy as determined by standard serum or urine b-HCG assay.

Arms & Interventions

Control

Intervention: Placebo

Thiamine

Receives thiamine

Intervention: Thiamine

Outcomes

Primary Outcomes

Effect of Thiamine Supplementation on Dyspnea

Time Frame: 8-Hour

Sitting Upright on Oxygen. Measured using a 10-centimeter visual analog scale (VAS). Measures are in units of millimeters (mm). A smaller number should be interpreted as a less dyspnea. A larger number should be interpreted as a more dyspnea. Less dyspnea is a better clinical outcome than more dyspnea.

Study Sites (2)

Loading locations...

Similar Trials